sorafenib has been researched along with Genetic Predisposition in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cen, J; Chen, X; Fu, Y; Gu, Y; He, S; Huang, X; Hui, L; Ji, Y; Li, C; Li, H; Li, Y; Lv, H; Meng, Z; Min, L; Qin, J; Qiu, Z; Shi, X; Shu, Y; Sun, L; Wang, C; Wang, P; Wang, W; Wang, X; Xie, F; Zhang, H; Zhang, Z; Zhou, H; Zhu, Z; Zhuang, L; Zou, K | 1 |
| Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M | 1 |
| Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y | 1 |
| Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
| Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G | 1 |
| Hoshida, Y; Newell, P; Villanueva, A | 1 |
| Caronia, LM; Phay, JE; Shah, MH | 1 |
| Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH | 1 |
3 review(s) available for sorafenib and Genetic Predisposition
| Article | Year |
|---|---|
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Male; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
Role of BRAF in thyroid oncogenesis.
Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Treatment Outcome | 2011 |
5 other study(ies) available for sorafenib and Genetic Predisposition
| Article | Year |
|---|---|
A Pharmacogenomic Landscape in Human Liver Cancers.
Topics: Animals; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Clinical Decision-Making; Databases, Genetic; Drug Resistance, Neoplasm; Female; Genetic Heterogeneity; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Patient Selection; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Niacinamide; Oxylipins; Pancreatic Neoplasms; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Urea | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors | 2016 |
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2013 |